Gapping up
Earnings/guidance: JBL +10.3%, ADBE +1.3%.
M&A: TSL +5.2% (shareholders approve 'going-private' transaction).
Drybulk/shipping stocks seeing momentum: TOPS +25.0%, CANF +19.2%, ESEA +17.6%, DCIX +13.4%, EGLE +13.0% (light volume; Oaktree Capital Management & Goldentree Asset Management filed amended 13D's), GSL +7.1%, DRYS +6.9%.
Gold/silver names higher as weaker dollar boosts precious metals: SA +2.4%, IAG +2.8%, AG +2.5%, AUY +2.3%, EGO +2.2%, GDX +1.6%, Select Russian stocks higher: MTL +4.6%, QIWI +3.2%, YNDX +2.1%, ABX +1.6%.
Other news: EVOK +38% (receives positive NDA submission guidance from us FDA for Gimoti), IONS +4.7% (earns $28 million from AstraZeneca (AZN) following AstraZeneca's completion of IND-supporting studies and license of IONIS-KRAS-2.5Rx), NOK +4.0% (still checking), MPEL +2.3% (issues update in relation to major initiatives to enhance shareholder value) SHPG +2.2% (still checking), QGEN +2.1% (still checking), CLLS +2.1% (announces recombinant DNA Advisory Committee's unanimous approval of UCART123 Phase 1 study protocols in AML and BPDCN; will host a conference call in the next coming days), MYL +1.6% (launches authorized generic for EpiPen).
Analyst actions: TXMD +9.2% (initiated with Overweight ratings at Cantor Fitzgerald), MGM +2.7% ( initiated with a Buy at Goldman), SQ +1.2% (initiated with a Buy at Needham; tgt $17), ERIC +1.7% (upgraded to Buy from Neutral at BofA/Merrill).